These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 19434899)
1. Hybrid structure-based virtual screening protocol for the identification of novel BACE1 inhibitors. Vijayan RS; Prabu M; Mascarenhas NM; Ghoshal N J Chem Inf Model; 2009 Mar; 49(3):647-57. PubMed ID: 19434899 [TBL] [Abstract][Full Text] [Related]
2. Virtual screening for beta-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228. Polgár T; Keserü GM J Med Chem; 2005 Jun; 48(11):3749-55. PubMed ID: 15916426 [TBL] [Abstract][Full Text] [Related]
3. Conformational transition in the substrate binding domain of β-secretase exploited by NMA and its implication in inhibitor recognition: BACE1-myricetin a case study. Chakraborty S; Kumar S; Basu S Neurochem Int; 2011 Jul; 58(8):914-23. PubMed ID: 21354237 [TBL] [Abstract][Full Text] [Related]
4. Novel non-peptide beta-secretase inhibitors derived from structure-based virtual screening and bioassay. Xu W; Chen G; Liew OW; Zuo Z; Jiang H; Zhu W Bioorg Med Chem Lett; 2009 Jun; 19(12):3188-92. PubMed ID: 19447035 [TBL] [Abstract][Full Text] [Related]
5. Triazole-linked reduced amide isosteres: an approach for the fragment-based drug discovery of anti-Alzheimer's BACE1 inhibitors. Monceaux CJ; Hirata-Fukae C; Lam PC; Totrov MM; Matsuoka Y; Carlier PR Bioorg Med Chem Lett; 2011 Jul; 21(13):3992-6. PubMed ID: 21621412 [TBL] [Abstract][Full Text] [Related]
6. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice. Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745 [TBL] [Abstract][Full Text] [Related]
8. Identification of new BACE1 inhibitors using Pharmacophore and Molecular dynamics simulations approach. Dhanabalan AK; Kesherwani M; Velmurugan D; Gunasekaran K J Mol Graph Model; 2017 Sep; 76():56-69. PubMed ID: 28710924 [TBL] [Abstract][Full Text] [Related]
9. Tripeptidic BACE1 inhibitors devised by in-silico conformational structure-based design. Hamada Y; Tagad HD; Nishimura Y; Ishiura S; Kiso Y Bioorg Med Chem Lett; 2012 Jan; 22(2):1130-5. PubMed ID: 22178553 [TBL] [Abstract][Full Text] [Related]
10. Sequential virtual screening approach to the identification of small organic molecules as potential BACE-1 inhibitors. Chiriano G; Sartini A; Mancini F; Andrisano V; Bolognesi ML; Roberti M; Recanatini M; Carloni P; Cavalli A Chem Biol Drug Des; 2011 Apr; 77(4):268-71. PubMed ID: 21244641 [TBL] [Abstract][Full Text] [Related]
11. Molecular docking based virtual screening of natural compounds as potential BACE1 inhibitors: 3D QSAR pharmacophore mapping and molecular dynamics analysis. Kumar A; Roy S; Tripathi S; Sharma A J Biomol Struct Dyn; 2016; 34(2):239-49. PubMed ID: 25707809 [TBL] [Abstract][Full Text] [Related]
12. From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). Cheng Y; Judd TC; Bartberger MD; Brown J; Chen K; Fremeau RT; Hickman D; Hitchcock SA; Jordan B; Li V; Lopez P; Louie SW; Luo Y; Michelsen K; Nixey T; Powers TS; Rattan C; Sickmier EA; St Jean DJ; Wahl RC; Wen PH; Wood S J Med Chem; 2011 Aug; 54(16):5836-57. PubMed ID: 21707077 [TBL] [Abstract][Full Text] [Related]
13. Pharmacophore based 3D-QSAR modeling, virtual screening and docking for identification of potential inhibitors of β-secretase. Palakurti R; Vadrevu R Comput Biol Chem; 2017 Jun; 68():107-117. PubMed ID: 28288354 [TBL] [Abstract][Full Text] [Related]
14. Fragment-based discovery of BACE1 inhibitors using functional assays. Godemann R; Madden J; Krämer J; Smith M; Fritz U; Hesterkamp T; Barker J; Höppner S; Hallett D; Cesura A; Ebneth A; Kemp J Biochemistry; 2009 Nov; 48(45):10743-51. PubMed ID: 19799414 [TBL] [Abstract][Full Text] [Related]
15. Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions. Klaver DW; Wilce MC; Cui H; Hung AC; Gasperini R; Foa L; Small DH Biol Chem; 2010 Aug; 391(8):849-59. PubMed ID: 20731541 [TBL] [Abstract][Full Text] [Related]
16. Impact of ligand protonation on virtual screening against beta-secretase (BACE1). Polgar T; Magyar C; Simon I; Keserü GM J Chem Inf Model; 2007; 47(6):2366-73. PubMed ID: 17944457 [TBL] [Abstract][Full Text] [Related]
17. Evaluating scoring functions for docking and designing beta-secretase inhibitors. Katharine Holloway M; McGaughey GB; Coburn CA; Stachel SJ; Jones KG; Stanton EL; Gregro AR; Lai MT; Crouthamel MC; Pietrak BL; Munshi SK Bioorg Med Chem Lett; 2007 Feb; 17(3):823-7. PubMed ID: 17107793 [TBL] [Abstract][Full Text] [Related]
18. Inhibitors of BACE for treating Alzheimer's disease: a fragment-based drug discovery story. Stamford A; Strickland C Curr Opin Chem Biol; 2013 Jun; 17(3):320-8. PubMed ID: 23683349 [TBL] [Abstract][Full Text] [Related]
19. Identification of Novel BACE1 Inhibitors by Combination of Pharmacophore Modeling, Structure-Based Design and In Vitro Assay. Ju Y; Li Z; Deng Y; Tong A; Zhou L; Luo Y Curr Comput Aided Drug Des; 2016; 12(1):73-82. PubMed ID: 26899408 [TBL] [Abstract][Full Text] [Related]
20. Protonation states of the catalytic dyad of β-secretase (BACE1) in the presence of chemically diverse inhibitors: a molecular docking study. Barman A; Prabhakar R J Chem Inf Model; 2012 May; 52(5):1275-87. PubMed ID: 22545704 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]